Kevin Zhou

Chairman & CEO

Danatlas Pharmaceuticals Co,Ltd.

Short Biography

Dr. Wenlai Zhou currently serves as the Chairman & CEO of Danatlas Pharmaceutical. He holds a Ph.D. in Molecular Biology from the University of Melbourne and completed postdoctoral research in Oncology at the UC San Diego School of Medicine under the mentorship of internationally renowned scientist Michael G. Rosenfeld, a member of both the U.S. National Academy of Sciences and National Academy of Medicine.Previously, Dr. Zhou served as Director, Chief Biologist, and Senior Vice President at Jacobio Pharmaceuticals, and as Director of the Oncology Drug Discovery Lab at Novartis in the U.S. With over 20 years of experience in drug R&D, corporate management, and strategic planning, he has more than a decade of expertise in the field of synthetic lethality. He possesses extensive experience in multinational corporation (MNC) collaboration negotiations and has successfully facilitated numerous internal and external project partnerships.Dr. Zhou is a national-level specially appointed expert and a distinguished overseas talent expert recognized by the China Association for Science and Technology. He has authored over 60 high-impact research papers and holds numerous patents.

Presentation Topic: Discovery and development of next generation anti-cancer drugs targeting synthetic lethality
Synthetic lethality has been employed for anti-cancer drug development for precision oncology. PARP inhibitors are the first type of anti-cancer drugs that have been developed based on synthetic lethality. However, PARP inhibitors face clinical limitations as significant side effects, poor patient tolerance, and development of drug resistance. Consequently, biopharmaceutical companies are actively developing next-generation anti-cancer drugs targeting synthetic lethal, such as with ATR inhibitors and PRMT5 inhibitors. Danatlas Pharmceuticals has focused on discovering novel synthetic lethal targets and developing next-generation anti-cancer drugs targeting synthetic lethal. Our pipeline prioritizes first-in-class (FIC) or best-in-class (BIC) candidates, with multiple synthetic lethal target programs already in or approaching clinical stages. Early data demonstrate best-in-class potential for these candidates. While committed to advancing our own next-generation synthetic lethal drug development, we are also looking forward to collaborative opportunities with pharmaceutical partners to accelerate pipeline development through combination of expertise from both sides. Our ultimate goal is to deliver innovative treatments to patients as soon as possible.